0001601830-24-000056.txt : 20240517
0001601830-24-000056.hdr.sgml : 20240517
20240517191141
ACCESSION NUMBER: 0001601830-24-000056
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240515
FILED AS OF DATE: 20240517
DATE AS OF CHANGE: 20240517
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Secora Michael
CENTRAL INDEX KEY: 0001855980
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40323
FILM NUMBER: 24961972
MAIL ADDRESS:
STREET 1: C/O RECURSION PHARMACEUTICALS
STREET 2: 41 S. RIO GRANDE STREET
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84101
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: RECURSION PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001601830
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 464099738
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 41S RIO GRANDE STREET
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84101
BUSINESS PHONE: (385) 269-0203
MAIL ADDRESS:
STREET 1: 41S RIO GRANDE STREET
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84101
FORMER COMPANY:
FORMER CONFORMED NAME: Recursion Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20140305
4
1
wk-form4_1715987475.xml
FORM 4
X0508
4
2024-05-15
0
0001601830
RECURSION PHARMACEUTICALS, INC.
RXRX
0001855980
Secora Michael
C/O RECURSION PHARMACEUTICALS
41 S. RIO GRANDE STREET
SALT LAKE CITY
UT
84101
0
1
0
0
Chief Financial Officer
0
Class A Common Stock
2024-05-15
4
F
0
11962
10.01
D
1219093
D
Stock Option (Right to Buy)
2.22
2030-03-03
Class A Common Stock
0
810135
D
Stock Option (Right to Buy)
2.22
2030-03-03
Class A Common Stock
0
685177
D
Stock Option (Right to Buy)
11.40
2022-02-04
2032-02-04
Class A Common Stock
0
3914
D
Stock Option (Right to Buy)
11.40
2032-02-04
Class A Common Stock
0
116684
D
Stock Option (Right to Buy)
8.55
2033-02-01
Class A Common Stock
0
404857
D
Stock Option (Right to Buy)
10.09
2034-02-09
Class A Common Stock
0
348380
D
Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
This transaction was executed in multiple trades at prices ranging from $7.44 to $7.70 The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
The option, originally for 1,500,000 shares, vests incrementally upon satisfaction of certain liquidity events.
The option, originally for 1,125,000 shares, vests as to one forty-eighth (1/48th) of the shares subject to the award one month after March 1, 2020, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter.
The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
/s/Jonathan Golightly, attorney-in-fact
2024-05-17